Lanlan Wei

Prof. Dr. Lanlan Wei


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Molecular Immunology
Verified
Journal Article
Closed access
XCXiaohang Chen
Xiaohang Chen
BYBingqing Yan
Bingqing Yan
HLHuihuang Lou
Huihuang Lou
ZSZhenji Shen
Zhenji Shen
FTFangjia Tong
Fangjia Tong
FZFengmin Zhang
Fengmin Zhang

1 August 2019 in Cancer Letters
Verified
Journal Article
Closed access
XCXiaohang Chen
Xiaohang Chen
EFEnhui Fu
Enhui Fu
HLHuihuang Lou
Huihuang Lou
XMXionghui Mao
Xionghui Mao
BYBingqing Yan
Bingqing Yan
LWLanlan Wei
Lanlan Wei

1 October 2016 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
JLJinyuan Li
Jinyuan Li
LYLibo Yu
Libo Yu
ZSZhenji Shen
Zhenji Shen
YLYushu Li
Yushu Li
BCBeibei Chen
Beibei Chen
LWLanlan Wei
Lanlan Wei

18 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LTLiping Tong
Liping Tong
MCMing Chu
Ming Chu
BYBingqing Yan
Bingqing Yan
WZWeiyi Zhao
Weiyi Zhao
SLShuang Liu
Shuang Liu
LWLanlan Wei
Lanlan Wei
MTDH promotes glioma invasion through regulating miR-130b-ceRNAs MTDH promotes glioma invasion through regulating miR-130b-ceRNAs

27 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
YJYourong Jiang
Yourong Jiang
SZSiwei Zhang
Siwei Zhang
LTLu Tang
Lu Tang
RLRui Li
Rui Li
JZJinglei Zhai
Jinglei Zhai
LWLanlan Wei
Lanlan Wei
The prognosis of human papillomavirus (HPV)-infected head and neck squamous cell carcinoma (HNSCC) is often better than that of HPV- cancer, which is possibly caused by the differences in their immune microenvironments. The contribution of macrophage, as a principal innate immune cell, to this phenomenon is still unclear. In this study, a single-cell atlas of 4,388 high-quality macrophages from 18 HPV- and 8 HPV+ HNSCC patients was constructed with single-cell RNA sequencing data. Eight macrophage subsets were identified from HNSCC, whereas their functional properties and developmental trajectory were delineated based on HPV status. Our results demonstrated that macrophages in HPV+ HNSCC exhibit stronger phagocytic ability, although the infiltration rate of macrophages decreased. From the results, a unique macrophage subset with TCR and CD3-specific signatures was identified from HPV-related HNSCC. These TCR+ macrophages potentially participate in the regulation of the TCR signaling pathway and phagocytosis. In conclusion, our results suggested that HPV could affect the infiltration rate, function, and differentiation of macrophages in HNSCC, whereas TCR+ macrophages play a critical role in the HNSCC microenvironment. These results provide new insights into the immune microenvironment of HNSCC and offer a valuable resource for the understanding of the immune landscape of HPV-related HNSCC, which will in turn help the development of immunotherapy strategies for the disease.

29 September 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JHJunming He
Junming He
YJYuting Ji
Yuting Ji
ALAimei Li
Aimei Li
QZQingmeng Zhang
Qingmeng Zhang
WSWuqi Song
Wuqi Song
FZFengmin Zhang
Fengmin Zhang
Human Papillomavirus (HPV) 16 infection is considered as one of the significant causes of human cervical cancer. The expression of the viral oncogenes like E6 and E7 play an important role in the development of the cancer. MiR-122 has been reported to exhibit a strong relationship with hepatitis viruses and take part in several tumor development, while the effects of miR-122 on HPV infection and the HPV viral oncogenes expression still remain unexplored. In this study, using RNAhybrid software, the potential binding sites between miR-122 and HPV16 E6 and E7 mRNAs were identified. Over and loss of miR-122 function showed that miR-122 could directly bind with HPV16 E6 mRNA and significantly inhibit its expression in SiHa cells, which was further confirmed by constructing the miR-122-E6-mu to eliminate the miR-122 binding effects with E6. The increase of the expression of type I interferon (IFN) and its classical effective molecules and the phosphorylation of signal transducers and activators of transcription (STAT1) protein indicated that miR-122 might enhance type I interferon in cervical carcinoma cells, which explained the significant reduction of HPV16 E7 and E6*I mRNA expression. This might be due to the binding between miR-122 and suppressor of cytokine signaling 1 (SOCS1) mRNA, which is the suppressor of interferon signaling pathway. Moreover, it was identified that the miR-122 binding position was nt359-nt375 in SOCS1 mRNA. Taken together, this study indicated that HPV16 could be effectively inhibited by miR-122 through both direct binding with E6 mRNA and promoting SOCS1-dependent IFN signaling pathway. Thus, miR-122 may serve as a new therapeutic option for inhibiting HPV infection.